<DOC>
	<DOCNO>NCT02058563</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety GSK 's trivalent MMR ( Priorix® ) , compare Merck '' MMR vaccine ( M-M-R®II ) , approve use US .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' Combined Measles-mumps-rubella Vaccine Volunteers , Seven Years Age Older</brief_title>
	<detailed_description>This study evaluate immunogenicity GSK 's trivalent MMR vaccine ( referred INV_MMR vaccine ) contrast US standard care ( M-M-R®II , Merck Company , refer COM_MMR ) use second dose subject 7 year age old . In study , INV_MMR vaccine may administer second dose person either history formal documentation least one dose immunization MMR vaccine . This study intend support licensure GSK 's MMR vaccine US .</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parent ( ) Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . Male female subject 7 year age old born December 31 , 1956* . *The exception health care worker born 1957 without evidence immunity mumps one dose live mumps virus vaccine recommend ; therefore population eligible enrollment study . For child 717 year age : Written documentation prior receipt 1 dose MMR vaccine administer first birthday . For adults 18 year age older : Prior receipt ( write verbal history ) least one dose MMR vaccine . Birth US . Written inform consent obtain subject parent ( ) /LAR ( ) subject ( assent obtain subject still legally minor line local rule regulation ) . Subjects stable health determine investigator 's physical examination assessment subject ' medical history . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject Has agree abstinent practice adequate contraception entire period start 30 day prior vaccination ( ) 3 month receipt study vaccination negative pregnancy test day vaccination . Child care . For child 717 year age : Previous receipt 1 dose measlescontaining vaccine . Use investigational nonregistered product study vaccine ( ) , period start 30 day precede day study vaccination , ( i.e . 30 day prior Day 0 ) plan use entire study period . Receipt measles , mumps rubellacontaining vaccine period start 42 day day study vaccination ( i.e . 42 day prior Day 0 ) . Chronic administration ( define 14 consecutive day ) immunosuppressant immunemodifying drug period start 180 day study vaccination plan administration immunemodifying drug entire study . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product period start 180 day prior study vaccination immunogenicity evaluation Visit 2 Visit 3 ( onedose twodose cohort , respectively ) . Planned administration/ administration live viral vaccine foreseen study protocol period start 30 day prior study vaccination end Visit 2 . Live intranasal influenza vaccine inactivate vaccine require age group may give time , include day study vaccination . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History measles , mumps , rubella disease . Known exposure measles , mumps , rubella , period start 30 day study start ( i.e . 30 day prior Day 0 ) . %</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Measles , mumps rubella disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>